Recruiting Prostate Cancer Studies in La Jolla
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-...
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer....
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment ...
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous ...
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The ...
TERPS Trial for De Novo Oligometastic Prostate Cancer
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis....
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC)....
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavo...
About Prostate Cancer Clinical Trials in La Jolla
Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.
There are currently 8 prostate cancer clinical trials recruiting participants in La Jolla, CA. These studies are seeking a combined 3,995 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Celgene, AstraZeneca and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Prostate Cancer Clinical Trials in La Jolla — FAQ
Are there prostate cancer clinical trials in La Jolla?
Yes, there are 8 prostate cancer clinical trials currently recruiting in La Jolla, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in La Jolla?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.
Are clinical trials in La Jolla free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.
What prostate cancer treatments are being tested?
The 8 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.
Data updated March 2, 2026 from ClinicalTrials.gov